Every material Form 8-K InspireMD, Inc. has filed with the SEC since July 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
InspireMD amended some of its outstanding Series J and Series K warrants with certain holders, lowering the exercise price on the affected shares to $0.7674 and tying their expiration to the anticipated FDA approval of CGuard Prime 80 cm. The company says that if the warrants are exercised in full, they could bring in up to $11 million in gross proceeds, which it expects to help fund the product launch, while existing shareholders face the potential dilution that would follow.
Amendments cover 50% of the Series J warrant shares and all Series K warrant shares held by participating holders, with the rest of the Series J shares unchanged at $1.3827.
New termination date is 5:00 p.m. Eastern on the earlier of May 15, 2028 or 20 trading days after the company announces FDA approval of CGuard Prime 80 cm, which it expects in Q4 2026.
The press release says up to $11 million in gross proceeds if the warrants are exercised in full; no new warrants were issued.
Some participating warrant holders are members of the company's board of directors.
InspireMD reported second quarter 2026 revenue of $1.8 million, flat year over year, with a gross loss of $774,000 after a U.S. recall of the CGuard Prime 135 cm delivery system. The net loss was $14.3 million, or $0.17 per share, compared with $13.2 million, or $0.26 per share, a year earlier, and cash and marketable securities fell to $30.4 million by June 30, 2026.
Q2 2026 total revenue was $1,771,000, down 0.4% from $1,778,000; international revenue rose 21% to $2,122,000 while U.S. revenue was negative at $(351,000) due to $734,000 of recall customer credits.
Q2 2026 net loss was $14,324,000, or $0.17 per share, versus $13,151,000, or $0.26 per share, in Q2 2025.
Cash and cash equivalents and marketable securities were $30,421,000 at June 30, 2026, compared with $54,211,000 at December 31, 2025.
The company said it initiated cost-saving actions after the quarter ended, expected to generate annual savings of approximately $9 million.
InspireMD notified Chief Commercial Officer Shane Gleason on July 23, 2026 that his position has been eliminated. His last day of employment is July 31, 2026. The filing does not describe a successor or the reasons for the elimination, so shareholders have limited detail on how the change affects commercial operations.
Position of Chief Commercial Officer Shane Gleason eliminated; notice given July 23, 2026
Last day of employment for Gleason: July 31, 2026
Filing contains no successor appointment or reason for the elimination
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every InspireMD, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →